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Abstract
Background: Decreased expression of the interferon-stimulated, putative tumour suppressor
gene XAF1 has been shown to play a role during the onset, progression and treatment failure in
various malignancies. However, little is yet known about its potential implication in the tumour
biology of clear-cell renal cell cancer (ccRCC).
Methods: This study assessed the expression of XAF1 protein in tumour tissue obtained from 291
ccRCC patients and 68 normal renal tissue samples, utilizing immunohistochemistry on a tissue-
micro-array. XAF1 expression was correlated to clinico-pathological tumour features and
prognosis.
Results: Nuclear XAF1 expression was commonly detected in normal renal- (94.1%) and ccRCC
(91.8%) samples, without significant differences of expression levels. Low XAF1 expression in
ccRCC tissue, however, was associated with progression of tumour stage (p = 0.040) and grade (p
< 0.001). Low XAF1 tumour levels were also prognostic of significantly shortened overall survival
times in univariate analysis (p = 0.018), but did not provide independent prognostic information.
Conclusion: These data suggest down-regulation of XAF1 expression to be implicated in ccRCC
progression and implies that its re-induction may provide a therapeutic approach. Although the
prognostic value of XAF1 in ccRCC appears to be limited, its predictive value remains to be
determined, especially in patients with metastatic disease undergoing novel combination therapies
of targeted agents with Interferon-alpha.
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Background
Renal cell carcinoma (RCC) of the clear-cell type accounts
for 3% of all adult malignancies and exhibits the highest
cancer-related mortality among urological cancer entities
[1]. Although the majority of patients (70%) present with
localized RCC at the time of diagnosis, approximately
40% progress to metastatic disease following tumour sur-
gery [2,3]. Once metastases are diagnosed, median sur-
vival rates drop to less than one year, mainly due to the
fact that RCC is largely refractory to conventional cyto-
toxic therapies [2,4]. The investigation of molecular
parameters involved in the development, metastatic
spreading and treatment resistance of RCC may help to
develop new therapeutic strategies as well as to identify
molecular makers that better characterize the aggressive-
ness of the individual tumour than standard clinico-path-
ological predictors [5-8].
The ability of neoplastic cells to evade apoptosis is known
to play an essential role for the development, progression
and treatment resistance of cancer [9,10]. X-linked inhib-
itor of apoptosis (XIAP) is the best characterized and most
potent member of the inhibitor of apoptosis (IAP) family
[11-13]. Its caspases-inhibitory activity accounts for the
protective effect against several apoptotic triggers includ-
ing irradiation and various anti-cancer drugs[14]. The pro-
survival activity of XIAP can be reversed by IAP-antago-
nists such as the mitochondrial protein Smac/DIABLO
(second mitochondria-derived activator of caspases/direct
IAP-binding protein with low pI) [15,16] and the nuclear
protein XAF1 [17,18]. XAF1 has been identified as an
interferon (IFN)-inducible tumour suppressor gene,
which's expression sensitizes cancer cells to several apop-
totic stimuli [18,19]. The pro-apoptotic effects of XAF1
may be mediated by direct sequestration of XIAP from the
cytosol to the nucleus, thus antagonizing the inhibition of
caspases [18]. More recently, XIAP-independent pathways
of apoptosis-sensitization by XAF1 have been identified,
e.g. the promotion of cytochrome c release, the prolonged
activation of p53 protein and its target gene expression as
well as the degradation of the IAP-family member survivin
[20-22]. XAF1 is ubiquitously expressed in normal human
tissues, but at comparably low or undetectable levels in
numerous cancer cell lines with high XIAP expression on
the other hand [17,18]. These data suggest that either
down-regulation of XAF1 or up-regulation of XIAP expres-
sion may promote the survival of tumour cells [17,23]. In
deed, over-expression of XIAP protein has been related to
RCC progression and an unfavourable outcome in RCC
patients [24,25]. Conversely, transcriptional down-regu-
lation of XAF1 expression has been reported to occur in
RCC [21] and low XAF1 mRNA tumour levels have also
been linked to impaired prognosis in RCC patients [26].
However, to further clarify the potential relevance of XAF1
for the development and progression of ccRCC, it is essen-
tial to investigate whether those mRNA-based findings
translate to the protein level. This study was done to
examine XAF1 protein expression in a large cohort of
ccRCC patients and to investigate the impact of XAF1
expression on clinico-pathological parameters and out-
come.
Methods
Collection of samples
Two-hundred-ninety-one patients (197 men, 94 women)
diagnosed with ccRCC at the Institute of Surgical Pathol-
ogy, University Hospital Zurich and the Institute of
Pathology, Charité – University Medicine Berlin between
1993 and 2005 were included in the present investigation.
The study has been approved by the Charité University
Ethics Commitee and the ethics committee of the Univer-
sity of Zurich. Non-neoplastic tissue samples of 68
patients from Berlin (55 men, 13 women) were subse-
quently included. Histological diagnosis was established
according to the guidelines of the World Health Organiza-
tion. All cases were selected according to tissue availability
and were not stratified for any known preoperative or
pathological prognostic factor.
Tissue Micro Array construction
A tissue-micro-array (TMA) was constructed as previously
described [27]. Briefly, suitable areas for tissue retrieval
were marked on standard haematoxylin/eosin (H/E) sec-
tions, punched out of the paraffin block and inserted into
a recipient block. The tissue arrayer was purchased from
Beecher Instruments (Woodland, USA). A punch diame-
ter of 0.6 mm was applied. Each tumour was represented
by two (Berlin) or one (Zurich) tissue core, respectively.
Immunohistochemistry
Formalin fixed paraffin embedded tissue was freshly cut
(3 μm). The sections were mounted on superfrost slides
(Menzel Gläser, Braunschweig, Germany), dewaxed with
xylene and gradually hydrated. For immunohistochemi-
cal staining, we used the Vantana Benchmark platform
with a standard antigen retrieval program (pressure cook-
ing). The primary polyclonal XAF1 antibody (Imgenex,
CA, USA, Catalog No IMG-379) was used in a dilution of
1:200. UltraVIEW™ was used as detection system with
Diaminobenzidin (Sigma-Aldrich, Munich, Germany)
serving as chromogen. Thereafter, the slides were briefly
counterstained with haematoxylin and aquaeously
mounted.
Evaluation of the immunohistochemical stainings
Two genitourinary pathologists evaluated the TMA on a
multi-headed microscope. The nuclear staining quantity
was evaluated with percentages of cells stained in analogy
to routine Ki-67 immunostainings in categories of 10%
intervals. The staining intensity was evaluated in a fourBMC Cancer 2009, 9:276 http://www.biomedcentral.com/1471-2407/9/276
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tire system from 0 (no staining) to 3 (strong staining).
Printouts of all four staining intensities were at hand as a
reference during the evaluation. An immunoreactive score
(IRS) was computed by multiplying staining intensity and
quantity. We used the median IRS value as cut-off for
dichotomizing patients into subgroups with low and high
XAF1 expression. Subsequently, the XAF1 expression was
evaluated in 68 normal renal tissue samples. A comple-
mentary subset of 50 papillary and 17 chromophobe RCC
was immunohistochemically analysed.
Statistical analysis
Statistical analysis was performed using SPSS, version
15.0. Fisher's exact tests and χ2-tests were applied to assess
statistical associations. Univariate survival analysis was
carried out according to the Kaplan-Meier method and
differences in overall survival were calculated using the
log-rank test. Multivariable analyses were performed con-
structing Cox proportional hazards models. All p values
were two-tailed, and those < 0.05 were considered statisti-
cally significant.
Results
XAF1 expression in normal renal tissue and clear-cell renal 
cell carcinomas
XAF1 was expressed in 64 of 68 benign renal samples
(94.1%), with a nuclear expression pattern. Nuclear XAF1
expression was consistently present in the epithelia of
tubules showing predominance in distal tubules over
proximal tubules (Figure 1A). Furthermore, mesangial
cells of glomeruli were consistently positive for XAF1. The
median IRS calculated for the normal renal samples was
40 (range of 0 – 180).
XAF1 expression was detected in 267 of 291 ccRCC sam-
ples (91.8%), likewise showing a nuclear expression pat-
tern. Although the intensity of XAF1 expression in tumour
tissue seemed to be more variable than in benign renal
parenchyma, the median IRS of 50 (range of 0 – 180) did
not differ statistically significant from that observed in
normal renal tissue. Figure 1B–C displays the different
staining patterns of XAF1 in ccRCC. Both, benign and
malignant samples lacking nuclear XAF1 expression also
did not display cytoplamatic staining but were completely
negative for this marker. A complementary analysis of 50
papillary and 17 chromophobe RCC mirrored the above
described findings concerning staining pattern and quan-
tity with negativity rates of 8% and 17.6% respectively.
The median IRS value for these tumour subtypes was 35
and 20. These complementary data were not included in
the further analyses.
Association of XAF1 with clinico-pathological tumour 
features and outcome
The clinico-pathological characteristics of the study popu-
lation are depicted in Table 1. Follow-up data was availa-
ble for all patients included in the study, with a median
follow-up time of 35 months (range of 1–139) months.
103 of 291 patients (35.4%) had died of ccRCC during
follow-up, but 50 patients had metastases at time of sur-
gery already. To correlate XAF1 expression to clinico-path-
ological tumour characteristics and prognosis, patients
were dichotomized into subgroups with high and low
XAF1 expression using the median IRS in ccRCC as a cut-
off.
Low XAF1 expression was significantly related to tumour
progression. The proportion of patients with low XAF1
tumour levels was significantly higher in the subgroup of
ccRCCs with T1/T2 disease compared to T3/T4 disease. (p
= 0.040). Moreover, patients with low XAF1 tumour levels
were more likely to suffer from poorly or undifferentiated
ccRCCs, compared to those with high expression levels (p
< 0.001). No significant associations were observed
between XAF1 expression and the metastatic status at time
of surgery or patients' age and gender (Table 1).
In Kaplan-Meier analysis, low XAF1 expression was signif-
icantly associated with a shortened overall survival (Figure
2). The mean overall survival was 91 months (CI 95%: 80
– 101) for patients with high XAF1 expression and 79
months (CI 95%: 68 – 89) for those with low XAF1
tumour levels (p = 0.018). In analogous univariate sur-
vival analyses, standard pathological parameters for out-
come prediction of RCC patients also reached statistical
significance (Table 2). In multivariable Cox regression
XAF1 immunohistochemistry Figure 1
XAF1 immunohistochemistry. A Normal renal tissue 
with prominent nuclear XAF1 expression in the tubuli and 
glomerular cells. B-D XAF1 expression in clear cell carcino-
mas with high (B), intermediate (C) and low (D) immunore-
active scores respectively.
A
D C
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analysis XAF1 expression did not provide independent
prognostic information, whereas the conventional prog-
nosticators, e.g. tumour stage, grade and the metastatic
status at time of surgery, maintained their prognostic
value (Table 3).
Discussion
This is the first study to demonstrate that low XAF1 pro-
tein expression is related to tumour progression in
patients with ccRCCs. Low XAF1 tumour levels are also
associated with a shortened overall survival of ccRCC
patients but do not provide independent prognostic infor-
mation when adjusting for standard pathological param-
eters for outcome prediction of renal cancer.
XAF1 mRNA is expressed at low or undetectable levels in
most cancer cell lines, and transcriptional down-regula-
tion in tumour as opposed to corresponding normal tis-
sues has been shown to occur at different frequencies in
gastric adenocarcinomas, colorectal cancer, urothelial car-
cinomas, malignant melanomas and also clear-cell renal
cell carcinomas [17,18,21,28-30]. Although these data
suggest a functional relevance of XAF1 down-regulation in
the process of malignant transformation, little is known
about protein expression of XAF1 and one cannot assume
that XAF1 mRNA levels regularly translate to the protein
level. In this context it has recently been shown that IFN-
treatment of various tumour cell lines lead to a strong up-
regulation of XAF1 mRNA but did not affect protein
expression [19].
In our study we detect XAF1 only as a nuclear staining in
both normal and malignant renal tissue. Interestingly,
Augello et al. found nuclear and cytoplasmic stainings for
XAF1 in neoplastic as well as non-neoplastic hepatic
lesions [31]. Zhang et al. and Sakemi et al. detected XAF1
only in the cytoplasm of normal and neoplastic hepatic
tissues [32,33]. Meanwhile, Shibata et al. detected XAF1
likewise only in the nucleus of basal cells of the gastric
mucosa and of gastric carcinomas [34]. This might hint at
different functions of XAF1 in different histological types
of tissue but it should also be mentioned that all these
studies, except ours and that of Sakemi et al., used differ-
ent XAF1 antibodies.
Table 1: Associations (χ2- and Fisher exact tests) between nuclear XAF1 protein expression levels and clinico-pathological parameters 
in clear-cell RCC
All cases Total (%) XAF1 low (%) XAF1 high (%) p-value
291 (100) 152 (52.2) 139 (47.8)
Gender 0.212
Men 197 (67.7) 108 (54.8) 89 (45.2)
Women 94 (32.3) 44 (46.8) 50 (53.2)
Age 0.101
≤64 142 (48.8) 67 (47.2) 75 (52.8)
>64 149 (51.2) 85 (57.0) 64 (43.0)
pT-status 0.040
pT1/2 145 (49.8) 67 (46.2) 78 (53.8)
pT3/4 146 (50.2) 85 (58.2) 61 (41.8)
Fuhrman grade <0.001
G 1/2 129 (44.3) 50 (38.8) 79 (61.2)
G 3/4 162 (55.7) 102 (63.0) 60 (37.0)
Metastases 0.276
M0/x 241 (82.8) 122 (50.6) 119 (49.4)
M1 50 (17.2) 30 (60.0) 20 (40.0)
Kaplan-Meier estimates of cumulative overall survival in  clear-cell RCC patients according to the nuclear expression  levels (high versus low) of XAF1 Figure 2
Kaplan-Meier estimates of cumulative overall sur-
vival in clear-cell RCC patients according to the 
nuclear expression levels (high versus low) of XAF1. 
Patients with low nuclear XAF1 expression levels (dotted 
line) display significantly shortened overall survival times 
compared to those with high nuclear XAF1 expression levels 
(bold line).
p=0.018
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In the current study we demonstrate that the median XAF1
protein expression level in ccRCC tissue does not differ
significantly from that observed in normal renal paren-
chyma. These data clearly point out that XAF1 expression
is not altered during the process of ccRCC development
and therefore suggest down-regulation of XAF1 to be irrel-
evant for ccRCC tumorigenesis. However, low XAF1
tumour levels may provide survival advantages of neo-
plastic cells in the presence of various apoptotic triggers
and may thus still have a role for tumour progression
[18,35]. Indeed, we found low XAF1 protein expression in
ccRCC to be associated with progression of tumour stage
and grade. These findings are in line with the results of
other studies, reporting XAF1 expression levels to
inversely correlate with tumour progression in gastric,
bladder and colorectal cancer [21,30,35], but again, these
investigations mainly focused on XAF1 mRNA expression
and thus hamper a direct comparison to our data. Moreo-
ver, based on the study design, it remains to some point
speculative whether down-regulation of XAF1 actually
plays a role for ccRCC progression or whether the
observed correlations only just constitute associated epi-
phenomena. Nevertheless, a correlation between low
XAF1 protein expression and progression of tumour stage
and grade has also been reported in hepatocellular carci-
nomas, supporting a possible functional relevance of
XAF1 down-regulation for the progression of various
malignancies including ccRCCs [32].
Corresponding to the observed associations of low XAF1
protein expression with advanced tumour stages and
grades, we found low XAF1 tumour levels to predict an
impaired prognosis in univariate, but not in multivariable
analyses. In our previous, real-time RT-PCR based investi-
gation, XAF1 mRNA expression levels did not relate to his-
topathological parameters, but independently predicted
an unfavourable clinical course of RCC patients [26]. So
basically both finding are absolutely in line in terms of the
adverse effects and associations of XAF1 down-regulation
in ccRCC. The described differences could be due to vari-
ations in the size of the cohort, but might also indicate
that XAF1 mRNA levels do not directly relate to the respec-
tive protein levels. Such differences have already been
published by Leamen et al. for XAF1 in melanoma cell
lines [19].
By analogy with down-regulation of XAF1 protein expres-
sion, up-regulation of its antagonist XIAP has also been
shown to be associated with RCC progression and poor
prognosis of RCC patients [24,25]. Since the decision
whether a cell undergoes apoptosis depends on the bal-
ance between pro- and anti-apoptotic factors like XAF1
and XIAP [18], the concurrent evaluation of these param-
eters in RCC, represented through the XIAP to XAF ratio,
may help to improve the prognostic value of these param-
eters compared to separate analyses. The feasibility of this
concept has recently been proven in an immunohisto-
Table 2: Univariate survival analysis (Kaplan-Meier) and log rank test
Characteristic No. of cases No. of events Two-year survival rate (± SE) in % p-value
XAF1 expression  291 103
Low 152 66 71.8 ± 3.7 0.018
High 139 37 84.7 ± 3.1
PT-Status < 0.001
pT1/2 145 28 92.3 ± 2.2
pT3/4 146 75 63.7 ± 4.0
Fuhrman grade < 0.001
G 1/2 129 25 88.1 ± 2.9
G 3/4 162 78 69.4 ± 3.7
Metastases < 0.001
M0/x 241 68 84.8 ± 2.3
M1 50 35 43.7 ± 7.3
Survival times of patients with clear-cell RCC according to clinico-pathological characteristics and nuclear XAF1 protein expression levels.
Table 3: Multivariable survival analysis (Cox regression)
Characteristic Relative Risk 95% confidence intervall p-value
XAF1 expression 1.200 0.792–1.820 0.390
pT-status 2.481 1.571–3.918 < 0.001
Fuhrman grade 1.736 1.083–2.784 0.022
Metastases 3.675 2.367–5.707 < 0.001
Characteristics are dichotomized according to Table 1.BMC Cancer 2009, 9:276 http://www.biomedcentral.com/1471-2407/9/276
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chemical investigation on the prognostic effect of XIAP
and XAF1 in gastric cancer [34].
Despite its uncertain value as a prognostic parameter,
decreased expression or inactivation of XAF1 has been
demonstrated to confer protection from various apopto-
sis-inducing triggers including 5-fluorouracil, etoposide
and  γ-irradiation [18,35]. Consequently, an abnormal
reduction of XAF1 expression, predominantly observed in
locally advanced and poorly differentiated RCCs, may
contribute to their extraordinary resistance to conven-
tional chemo- and radiotherapy [4]. Furthermore, XAF1
has been identified as an interferon-stimulated gene
(ISG), which's expression is up-regulated by the exposure
to IFN-α and IFN-β, resulting in a sensitization of various
tumour cell lines to tumour necrosis factor-related apop-
tosis inducing ligand (TRAIL)-induced apoptosis [19,36].
Up-regulation of XAF1 protein expression augmented
IFN-induced apoptosis, whereas down-regulation con-
ferred protection from IFN-induced apoptosis in the renal
cell carcinoma cell line ACHN [37]. This indicates XAF1
not only to constitute an ISG, but also to mediate the anti-
tumour effects of IFN. Therefore, one can speculate that
both, the failure of IFN to induce XAF1 expression in IFN-
resistant tumour cells as well as an abnormal reduction of
XAF1 protein expression, may contribute to the poor
response rates of ccRCC patients to IFN-based immuno-
therapy [38,39]. Although single-agent IFN-α therapy is
meanwhile obsolete for metastatic ccRCC patients, this
aspect deserves further investigation, since its combina-
tion with targeted agents like Bevacizumab is an estab-
lished therapeutic option for first-line treatment [40].
Considering that XAF1 has recently been reported to pre-
dict treatment response of bladder cancer patients to
chemotherapy [41], it appears also reasonable to evaluate
its predictive value in ccRCC patients as well. Finally,
XAF1 itself may potentially provide a therapeutic agent, as
its induction by adenoviral delivery recently proved to be
promising strategy for the treatment of cancer [42].
Conclusion
In conclusion, low XAF1 protein levels in ccRCCs were
related to poor tumour differentiation, advanced tumour
stages and unfavourable outcome. Although XAF1 did not
provide independent prognostic information, these
observations fit well with the pro-apoptotic activities of
XAF1 and suggest its down-regulation to play a role dur-
ing the process of ccRCC progression. Further studies aim-
ing to evaluate the predictive value and therapeutic
potential of XAF1 in ccRCCs are warranted.
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